Ratings Esperion Therapeutics, Inc.

Equities

ESPR

US29664W1053

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-07 pm EDT			5-day change	1st Jan Change
2.37 ^USD	+11.79%		+20.30%	-20.74%

May. 07	Investor Sentiment Muted After Rate Cut Optimism, Stifling US Equity Futures Pre-Bell	MT
May. 07	Top Premarket Gainers	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
According to Refinitiv, the company's ESG score for its industry is poor.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Thanks to a sound financial situation, the firm has significant leeway for investment.
The stock, which is currently worth 2024 to 0.67 times its sales, is clearly overvalued in comparison with peers.
Given the positive cash flows generated by its business, the company's valuation level is an asset.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The company has insufficient levels of profitability.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Over the past four months, analysts' average price target has been revised downwards significantly.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
ESPERION THERAPEUTICS, INC.	-20.74%	402M	D+
ELI LILLY AND COMPANY	+33.43%	690B	C+
NOVO NORDISK A/S	+26.43%	546B	B
JOHNSON & JOHNSON	-5.12%	358B	C+
MERCK & CO., INC.	+19.59%	323B	B-
ABBVIE INC.	+4.89%	287B	C+
ASTRAZENECA PLC	+14.32%	235B	B+
NOVARTIS AG	+5.79%	199B	B-
ROCHE HOLDING AG	-9.49%	195B	A+
AMGEN INC.	+4.26%	161B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes